News articles about Galapagos (NASDAQ:GLPG) have trended somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Galapagos earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.0400388528111 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of Galapagos stock traded down $2.43 during trading hours on Thursday, reaching $99.91. The company’s stock had a trading volume of 24,632 shares, compared to its average volume of 98,586. The stock has a market capitalization of $5,201.66, a PE ratio of -38.47 and a beta of 1.95. Galapagos has a fifty-two week low of $72.90 and a fifty-two week high of $121.09.
Galapagos (NASDAQ:GLPG) last announced its earnings results on Thursday, February 22nd. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.02). The firm had revenue of $58.37 million during the quarter, compared to analysts’ expectations of $42.84 million. Galapagos had a negative return on equity of 12.27% and a negative net margin of 74.70%. equities analysts expect that Galapagos will post -3.91 earnings per share for the current year.
Galapagos Company Profile
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.